MedTrace Logo

CETO First in Human Trial

NCT04529018 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-08-27

No results posted yet for this study

Summary

The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, \[18F\]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).

Conditions

  • Primary Aldosteronism

Interventions

COMBINATION_PRODUCT

[18F]CETO

\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism

Sponsors & Collaborators

Principal Investigators

  • Mark Gurnell, PhD, FRCP · University of Cambridge

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-03
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04529018 on ClinicalTrials.gov